Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.71 |
| ▸ | CLPP | Q16740 | 1/20 | 0.71 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152444 | 1.00 | GRM5 (0.71) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL415297 | 0.92 | HSD11B1 (0.78) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL193948 | 0.92 | HSD11B1 (0.78) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL4151196 | 0.91 | HSD11B1 (0.80) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL4151187 | 0.91 | HSD11B1 (0.80) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL4130483 | 0.89 | GRM5 (0.72) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL4130486 | 0.89 | GRM5 (0.72) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL193323 | 0.87 | GRM5 (0.70) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL193322 | 0.87 | GRM5 (0.70) | GRM5CLPPHSD11B1POLBTSHR | |
| SCHEMBL193680 | 0.83 | GRM5 (1.00) | GRM5CLPPHSD11B1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2009-08-06 | — | — | US | claimed |
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM3 | GRM5 1/4885CLPP 4656/4885HSD11B1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.